RxDoctor Payments Data

Michael Magpile, MD

Internal Medicine · la Mesa, CANPI 1316988843

Payments from drug & device makers

$1,574in general payments, 2019–2025

Across 84 payments — averaging $18.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$324
  • Novo Nordisk$292
  • Astellas Pharma US Inc$150
  • Pfizer$142
  • AstraZeneca$125
  • Novartis$92
  • plus $449 from 16 others

What the payments were for

  • Food & beverage$1,574100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,574 in reported general payments places this provider in the 80th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$257,995
Medicare patients
658
Services billed
9,310

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin99$139,738
EliquisApixaban81$105,984
JanuviaSitagliptin Phosphate47$70,724
OzempicSemaglutide61$65,553
TrulicityDulaglutide32$50,453
MounjaroTirzepatide34$35,146
CreonLipase/Protease/Amylase22$21,938
FarxigaDapagliflozin Propanediol14$21,035
XareltoRivaroxaban14$17,660
MyrbetriqMirabegron13$14,540
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen225$7,337
Atorvastatin Calcium581$7,007
Valsartan244$6,857
Levothyroxine Sodium407$5,341
Rosuvastatin Calcium344$5,116

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$20$139,73899 claims
PfizerEliquis$142$105,98481 claims
Lilly USA, LLCTrulicity, Mounjaro$324$85,60066 claims
MerckJanuvia$20$70,72447 claims
Novo NordiskOzempic$292$65,55361 claims
AbbVieCreon, Synthroid$73$24,22982 claims
AstraZenecaFarxiga$125$21,03514 claims
Johnson & JohnsonXarelto$48$17,66014 claims
Astellas Pharma US IncMyrbetriq$150$14,54013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 13,581 internal medicine providers in California.

Other internal medicine in la Mesa

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →